Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bond density, or for the treatment of various disorders in mammalian and avian species, X17251.

Abstract: Systems, and programming for improved arrangement and administration of syndicated loans using computer networks. Each of a plurality of bookrunners is authorized to invite any number of other bookrunners, as well as any number of loan participants, or underwriters (i.e. investors or lenders), to participate in offering and administering a loan, typically by providing various forms of information describing the proposed loan, including the borrower, the proposed terms, and possibly any potential participants in making the loan. Invitees who accept such invitations may be associated with the inviting bookrunner, and upon being accepted as participants may be granted by the bookrunner access to various sets of communications, documents, and other information concerning the proposed loan.

Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.

Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Abstract: An electronics card for an electronics module comprises a wireless transceiver for communication with a second wireless transceiver external to the card. In addition, an electronics module comprises such an electronics card.

Abstract: An electronics module for a well installation comprises a wireless receiver for receiving data and/or software from an external source.

Abstract: Systems, and programming for improved arrangement and administration of syndicated loans using computer networks. Each of a plurality of bookrunners is authorized to invite any number of other bookrunners, as well as any number of loan participants, or underwriters (i.e. investors or lenders), to participate in offering and administering a loan, typically by providing various forms of information describing the proposed loan, including the borrower, the proposed terms, and possibly any potential participants in making the loan. Invitees who accept such invitations may be associated with the inviting bookrunner, and upon being accepted as participants may be granted by the bookrunner access to various sets of communications, documents, and other information concerning the proposed loan.

Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for thereaputic purpose are also provided.

Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: A novel crystal form the pharmaceutical compound olanzapine, processes for its preparation and its pharmaceutical use are disclosed.

Abstract: Methods, compostions and kits comprising antibodies for the treatment of neoplastic, autoimmune or other disorders are provided.